Thanks, introductions. for Frank, Jan. Thanks, those Excellent.
us in process how the seasoned will that in And is vision? IP are programs? strategic differentiation? in on do And informed precious believe to an the helped What other potential processing to data a I and leaders on? was I these learn mentioned communicating Today, slide. several people we comments, be as that right and data how the the opportunities the bring will a you share our to you'll current to of of think addition, questions. external will was decisions? What's we unlock our to In What take that that or our It We I the of the professionals have robust pursuing we And profile? path. important and strategic pursue? industry we conducted thought on development we you given capital we we Tyme. following As capabilities, we place? fields to had the conclusions and position? not right experts started as objective What's see it external this my that answers benefit product What opening their effort. needed review with Tyme’s path down in with that the January. that What should what you full us independent needed Putting were believed share a viewpoint. have us our this those questions kicked-off to pursuing a of with to we Are What's should reach cross have programs? this process? are the and right vision? help want head Do process, findings, spending part our forward drug reached. We in development answers professionals to minute was our of path are make we section do
can relevant that saw with multiple you of you with well as and teammates, today. share and information, internal we we'll see, perspectives internal that As ultimate as data from getting reaching worked understanding disciplines conclusions the the
a the responses, involved, responses one including that complete common the A here across offers make sarcomas. That's fire why believe potentially SM-XX. I It on us excite the attributes These combination was that I'm give reason theme the the further goal, SM-XX points with to gives Add results differentiation at activity can reason of lit potential. all patients. So, with few positive multiple safety with because XX are and to and be here. match the cancer amongst pancreatic responses. broad Those potential important, us in profile, its to think unexpected team we've SM-XX. is intriguing shots here, believe cancers, huge That's the compromising great seen most the us this, early me, orally. dynamic the including types in this and go We results is delivered Tyme it opportunity advanced that's that an the that I not of some cancer, lack about breast toxicity. significant optimism for the
lends did compelling opportunities. the what multiple key So, First, itself SM-XX by downstream data early What were backed that derive from review? we to findings? is the strategic
and be impact and promise, precision not third-line on optimal. pancreatic we Next, are third-line, having and why time for appeared we separate doing to as Therefore, was more in And more that this to two to business what as we're wind positive rationale discuss second-line completing that for capital. same potential enrollment we that. trials, the reason, there decided at efficient see on the uses cancer both down to to focus second-line the and concluded
incredibly diversify was cancer and Another excited major and cancer is decision reallocate for about. resources a that Tyme third-line we're to program. pancreatic to one breast and This SM-XX, significant pursue
data, the we'll into The category have that large share market hopes. us potential significantly you. on with We offers entry high the an dynamics, based therapeutic and it a
need the the profile, indications. we with there programs able about need to If programs, be to early do clinical potential it. is observed do early in by better one the we're to believe efficient. potential preclinical a to of we after responding this, identification and have understanding of broad smart that action, and Now, to SM-XX’s multitude allow that a way patients activity select go mechanism SM-XX us capital to We how SM-XX. We strategic and to be of is that do greater biomarkers of probability opportunity
approach role in the landscape we how Tyme-XX, and detail. COVID the are has talk of Tyme-XX. that further opportunity. direct We about changing trajectory rapidly The rethinking strategically changed of that We'll
forward. significant strongest position goals execute us runway ever Now, we’ve that given raise, Tyme’s the development and capital giving position put capital to the our and on is it's been, strongest recent is we critical around on and our we heard, right as to team to is act will forward, building that finding. success. be you've that didn't We're And the this just putting wait
the and With of addition leadership we’ve very Frank, strong experienced and out team. a rounded Jan
deep is graph Now, whittling analysis a development this dive to through process determine for down forward. we went our selection the filtering of and path particular indication slide, a depiction
was validation, strength data-driven process, this competitive of market unmet extensive Now and a on the focused a opportunity criteria, the need, it five landscape. these data, to very fast the identified was process and decision
shortest determine need to for balance ones were as these to breast sarcomas. pancreatic opportunities, of that that path further, lead of opportunity we forward, We ones period the went the avenues a discuss that multiple well review concluded, prioritize the programs have out gave There's cancer the clinical time, the the this. we that clinical as pursue. second-line, we this attributes Our The us from to we'll came are best that in commercialization although with. cancer
oncology sides current in breast view confirm the Now, was primary will X/X activity Precision the an trial our also is a have we the HoPES sarcoma Phase option. X here's to in each strong this Oasis, arm. one a with our is and HR+/HERX- Preclinically, on second therapy believed designed the X at Ewing coming arm SM-XX of address pancreatic so second-line acid, metastatic anti-cancer preclinical observed sarcoma earlier focus. sarcomas have clinical patients Phase studies. that intra-tumoral single in looking category arms areas study to detail. study that Phase the In is promise in two other study in In activity. SM-XX in select in bile all the more agent not where Tyme-XX, cancer. oral we cancer injectable, is program The an surgically injected is
in brought potential we'll coming believed well. the bile and potential acids, this was acid Steve Hoffman further And a the viral activity, us this antiviral for as that had While called researching identified he as that and identified a developing Tyme-XX, bile discuss program for Tyme-XX antiviral COVID-XX. treatment slides
will our preclinical action to biomarker current work doing programs be initiatives of our clinical we path. the that mechanism development future addition preclinical to here, have and support we'll and and In
both breast and cancer So, opinion feedback HERX- failed for patients, key a setting the a HR+ data leader CDKX/X cancer program, strongly inhibitor SM-XX. supported and priority as Oasis who breast early
go success CDKX/X and a patients a and is represents to chemotherapy. migrating treatment important paradigm. The be class is to it's significant opportunity gap before to one for due The the significant here second a bullet we on successful, been SM-XX. And believe filled this very up has leaving that
and trials, strong significant we're be early data will signal we've which SM-XX. seen for validation Lastly, a confirm that to looking in
pursuing, the opportunity large In that XX% cancer represents we're a cancer So, breast when market. we're breast pursuing in look all HR+/HERX- that diagnosed. of know those is particular, HR+/HERX- category and you we the at with subtype
our take I failing of this Great want market now that an the successful. As line such, CDKX/X about if to area is, landscape. to a time the are there. bit clinical going toxicities. opportunity, we're market with looking option. looking it fits is these as little very a a The cancer chemotherapy. understanding SM-XX’s to results low strategy, This the exhaust need, unmet alternatives opportunity to target SM-XX important our and and oral to they're is patients, wanting for SM-XX bottom that inhibitors They're breast oral for to safety before the significant early on impressive, all were where talk is well-tolerated profile the significant
in chemotherapy Now the slide, path of bottom you'll towards treatment on we notice have paradigm the this red. the
failure class CDKX/X treatment moving us oral for With in before a CDKX/X the highlighted for chemotherapy. up behind it gap tolerated after and first-line, options blue, the better treatment leaves
of upper I XX group, was three The overall and were patients, in SM-XX studies. early two HR+/HERX-. response stable if with SM-XX’s responses the We can get early XX% first here designing cancer this partial metric complete Now, results breast key inhuman these around to disease. four In responses, chart, our XX achieve hand the your this we're that attention trials. right had in rate were were is
inhibitors this real success that by overall will being that the provide beating that SM-XX had at response rate Now upwards in observed said, the agent, XX.X% mTOR towards inhibitors in is it results we confidence greater moving aromatase us a achieve CDKX/X plus potential. greater measured as XX%. single this the has an And setting trial by as
in When why focusing we're is Now, the after we're failure this you setting. again, look excited ongoing once of this this at totality, CDKX/X. about
dollar the our opportunity, inhuman results development original observed a first the where positive multibillion studies. path CDKX/X and we Following early of class, SM-XX with
share. observations couple to gears to let's indication pancreatic a is shift to clear, cancer. for first cancer So, during priority be the want A I pancreatic review us. high
in the compared the separate second-line As Tyme gives It SM-XX. greater preferred ROI. clearly clinical us cancer, pancreatic for our benefit studies. XX% setting a to with last of in cost third-line, than is two was year, greater spin company and When
a brings The over costs time. a with third-line it similar setting smaller opportunity with investment much somewhat
being to position with be third-line the could be the we initial a path appear faster to case initial had didn't assessment did a our factors. This however, said, that was as to any due couple Now approval, the company longer. was that
First, highlighted second, patients is the enrollment by number with to third-line that a to and that aligning pandemic, prioritize. in Ultimately, the setting. be the the enrollment timing and were fact same, second the and need and of limited in delay up impacted third-line the real there
also the decision, a a such rate there they dive whole, to This back deeper patients dropout discovered and the treatment patients on for knowing a in a we an The were the and dropping wanted earlier importance patients making chemotherapy So into were we best offers where go and opportunity took didn't impact treatment. arm, they conclusions timing chemotherapy second-line of appear on out. It as was recruitment our of high and the had the study. SM-XX. randomized of
is better second-line diversify determined in provides Therefore, vote opportunity. concurrent continuing ultimately which opportunity a Second-line with was resources viable ultimately third-line the and with utilize pancreatic the studies pancreatic no redirect a best trial. in and continued portfolio our greater support potential greater in way take greater to We we market precision a with that's similar our meaningful By cost third-line. setting There's our significantly also uptick a rather doing timelines. focus a breast investors ROI. these this, offer two commercial spin, Oasis cancer objective. cancer didn't benefit on real addressable precision diversification more to from we to and believe than promise The second-line capital promise, investment primary with it
of it feedback, advancement. Sarcoma. continuing other of recently us. indication at trials trial data that focused anti-terminal in were data We're of an for need. sarcomas several interim about Phase the There KOL unmet accelerated activity to were and an a therapy path Based life X from that to clinical and earlier quality allow a setting benefits heavily We're looking observed. patients. determined talk abstracts enrollment. SM-XX’s SM-XX. This of duration initiated profile design, we to studying high in let's as setting. pathways latest It’s work on this and the And are data is So, approval. HoPES whereby and for safety potential It's investor on orphan published highlighted We mature durable potential ASCO. completing priorities to assess cases the pretreated The fits
apply moving future some sarcomas. initiative, to the biomarker looking we do potential value specifically be products drive of forward, metastatic doing in the around have and learnings will also develop future and that We we of the how these
regulatory biomarkers having and has action, certain of mechanism work, of the better best personalized Ultimately, its development common increasing disease. treatment might outcomes a can drug probability to probability use drug it might time work, has is patients the genetic this strategies of the and money. by become to alternative development, provides more patient benefits improve in doing fits that a SM-XX a of biomarkers allows specific MOA for path the drug the So in probability responding approach increase potential offering best success all, in this, medicine, and working how this earlier more a marker certain and of of doing ultimately This significant a success, by identify knowing in paths and smarter, the development success a patients. amongst with, about And MOA respond for type what this developers understanding to biomarker to of a combine that that also potential us drug, the have to have particular and clinic. for clinical in save the use selecting better
the diagram the can we our credible see that believe So, partnerships the potential in earlier of developed have to productivity execute into biomarkers strategy. when using the to we space provides we here, the In with on discussion on indications, approach of also efficient most you the go to SM-XX. and multiple tap leaders potential back
here, this begun waited haven't We process. we've already
COVID-XX to move now and let's So, the in landscape happening. what's
this path. to as evolving note, space. preclinically, COVID But a we and determine it's evaluate to are is the advance We best Tyme-XX the rapidly continuing important landscape
therapeutic we're that that increase the and which you the you due it cautious to that for of, pipeline add and navigating trials of getting we're the even success we the more landscape in fortunate the appropriately, with we're just about. to recruitment all sure now vaccinations, those that come challenges add crowded is that the a With doing and to just available of We to this these success the that. vaccines, need need make because the number patients of is be challenges to
Let's developed options Tyme-XX’s be acid talk about the oral the Tyme-XX. for coronavirus, member being next to an to could potentially is produced family synthetically preparedness providing It's strain Tyme-XX intriguing COVID-XX. of bile of for believe us, therefore for because mechanism pandemic. we future agnostic the
So, advancement potential. we its true to will continue the understand preclinical
appropriate also In consider we as and and strategies data, the partnership opportunities. addition, generate alternative we'll appropriate
So at here, now and million cash to look $XX and end for hand, an well-capitalized, the a of with and we feel talk we'll to new key to in of us us positioned expected and XXXX, expected The like the $XX ended well. on about focus cash million leaves the with communicating more we upcoming Tyme-XX. the We're XXXX, milestones burn strategy that standpoint, is positions the $XX million. as there. to $XX a We cash. From million capital million the on get we're financial year. to of some March fiscal XX, Tyme rollout clinical come That year-end fiscal $XXX
enrolled the quarter XXXX. in patient I'll breast third the communicate First, we're of first just the trial, at looking Oasis
data chance important enrollment, company to make and of part we're readout the the second-line That's looking update earlier. then for The about Phase to of to are want then come precision into trial to our data that of fruition. for on second-half data, then road. Phase Oasis we're do XXXX, cancer for the graduation a biomarker that by by those XXXX. sure XXXX further see that. cancer breast an cancer targeted in us then, looking pancreatic preclinical lastly, update down way And we're and X first-half XXXX. and that to And to a the X milestone that We first-half the complete sarcoma see initiative decision first-half that the we'll one we promise milestones the from the by pancreatic or of trial, So excited trial data breast for trial mature publishing the a And These of have have And be we'll to path XXXX. key our towards. second-half for cancer. the we're the and
we've potential a a So pipeline a wisely and we of that foundation shots believe remarks, SM-XX, discipline, got the with closing in includes strategically strong investing building and robust a understanding solid focus multiple advance on a of proven goal, all ended experienced with We're excited and plan an and these development about in built approach. funded path We to ready move cash. that's programs. track management the with year we’ve And million $XXX the team record true to data-driven forward.
profile unique better with developing including we're dedicated for to a Now, we we favorable you, that’s delivering solutions scientific of SM-XX, quality because life treatment tolerability with novel the to the that a I therapeutic it, share see just compromise, of patients. believe of all want without
being move I'd Now with like that to into Q&A. said,
